Soft Tissue Sarcoma Trial Results
6. Imatinib Mesylate (Gleevec™) Shows Promise for Type of Gastrointestinal Tumor
(Posted: 07/20/2001, Reviewed: 12/20/2005) - Imatinib mesylate (Gleevec™), a new cancer drug approved on May 10, 2001, for the treatment of some types of leukemia, now appears also to work in a rare type of cancer called gastrointestinal stromal tumor (GIST). Two reports presented from early clinical trials of the drug, also called STI571, were presented at the 2001 annual meeting of the American Society of Clinical Oncology in San Francisco on May 14.
< Previous 1 2
|
